Archive for the 'Biphasic or Mixed' Category
Combination of epithilioid and sarcomatoid mesothelioma types. Approximately 20-35% of cases are classified as mixed or biphasic mesothelioma.
August 7th, 2007. Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy
Conclusions: High-dose hemithoracic RT appears to limit in-field LF compared with MDRT. However, DF remains a significant challenge, with one-half of our patients experiencing DF.
June 19th, 2007. Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin
Remarkably, one xenograft from MM-Z03E revealed overexpression of p53 and widely invasive growth. In conclusion, both cell lines are useful in vivo and in vitro model systems to study the underlying genetic mechanisms of biphasic differentiation in MM, which can be of certain value considering the increasing relevance of assessing MM tumor biology for the clinical management of this disease.
June 2nd, 2007. A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation
Conclusion: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma. Due to the high costs of such a study, a two-stage method is
May 15th, 2007. Intracavitary mass as the initial manifestation of primary pericardial mesothelioma: a case report
Significant amounts of pleural fluid and huge tumors within both pleural cavities emerged. The patient died due to respiratory and circulatory insufficiency 11 months following the diagnosis.
Posted in Biphasic or Mixed, Carboplatin, Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Gemcitabine (Gemzar), Immunohistochemistry or IHC, Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 11th, 2007. A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid
Although CYFRA elevation in the serum and/or the pleural effusion in MPM patients has been previously reported, it has not been reported in any of the 5 MPM patients reported to have G-CSF elevation. Therefore, this is the first reported case of G-CSF-producing MPM with CYFRA elevation in both serum and the pleural effusion.
March 17th, 2007. Biphasic malignant mesothelioma cases with osseous differentiation and long survival: A review of the literature
Both patients survived 39 and 69 months, respectively. To our knowledge, these two cases with biphasic malignant mesothelioma and osseous differentiation with long survival are the first to be described from Central Anatolia.
March 16th, 2007. D2-40 and calretinin – a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
66. These data indicate that a combination of calretinin and D2-40 will improve diagnostic accuracy for spindle cell lesions of the pleura, whereas almost all epithelioid mesotheliomas are identified by calretinin alone.
February 24th, 2007. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells
5, previously not identified in human cells, were detected by mass spectrometry. Our data show differential expression of TrxR1 mRNA forms in malignant mesothelioma of different phenotype, and investigation of alternative transcript variants of TrxR1 could be a valuable tool in the diagnostics and characterization of tumors.
February 20th, 2007. Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia
Conclusions: Radical oncologic cytoreductive surgery combined with intraperitoneal perioperative chemotherapy provides good results with prolonged survival in selected cases, although morbidity is high. Based in our experience, biphasic sarcomatous mesotheliomas should be excluded from
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Sarcomatoid, Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Survey of surgical treatment of malignant pleural mesothelioma in Japan
086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Malignant pleural mesothelioma
4% and the median survival time in patients with epithelial mesothelioma was 30. 6 months.
Posted in Biphasic or Mixed, Chemotherapy, desmoplastic, Diagnosis & Differentiation, Full Archive, Pleural, Pleural Biopsy, Sarcomatoid, Survival, thoracoscopy, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Diffuse malignant pleural mesothelioma
Median survival time after diagnosis was 3 (range, 0 to 51) months. Of the 11 patients, 7 (64%) died within 6 months after the first presentation, and only 1 (9%) lived longer than 2 years after diagnosis.
Posted in Biphasic or Mixed, Chemotherapy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 26th, 2006. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Conclusions: The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome. New targeted therapies are awaited for further improvements in the treatment of this disease.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Epithelioid, Full Archive, Gemcitabine (Gemzar), Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 25th, 2006. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epithelioid, Full Archive, Peritoneal (Abdominal Mesothelioma), Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 8th, 2006. Pathology of primary tumors and pseudotumors of the pleura
Histological types include mesothelioma, epitheliod, biphasic or sarcomatoid tumors as well as primary lymphoma and mesenchymatous tumors which include solitary fibrous tumor, epithelioid hemangioendothelioma and angiosarcoma and synovialosarcoma. We detail here the new WHO classification 2004 explaining the different entities, excluding metastatic tumors which are the most frequent tumors of the pleura.
April 25th, 2006. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
To characterize the biological differences between Y-MESO-8A and Y-MESO-8D, we carried out cDNA microarray analysis and detected genes that were differentially expressed in these two cell lines. Thus, our new MPM cell lines seem to be useful as new models for studying various aspects of the biology of human MPM as well as materials for the development of future therapies.
Posted in Biphasic or Mixed, Epithelioid, Full Archive, Gene Therapy, New & Novel, Pleural, Sarcomatoid, SV40, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 2nd, 2006. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Conclusions: The results show that malignant mesotheliomas have a lower expression of claudins 1, 3, 4, 5, and 7 than adenocarcinomas, and their expression could thus be used as an adjunct in differential diagnosis between the two. The difference was most evident for claudins 3 and 4, which were nearly as good as calretinin in mesothelioma detection. Sarcomatoid and biphasic mesotheliomas showed expression of these claudins only occasionally, which could be due to or contribute to their less epithelial appearance.
January 11th, 2006. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
It is important for pathologists to be aware that mesotheliomas can present rhabdoid features, not only because they can be confused with other malignancies that can exhibit a similar morphology, but also because of their apparently unusually aggressive behavior. The value of immunohistochemistry and electron microscopy in the differential diagnosis of these tumors is discussed.
December 16th, 2005. Malignant biphasic pleural mesothelioma metastatic to the liver diagnosed by fine-needle aspiration
Recognition of the cytomorphologic features inherent to mesothelioma cells on FNA material may become important for proper patient management. To the best of our knowledge, the diagnosis of malignant pleural mesothelioma metastatic to the liver made by FNA has not been previously documented.
November 21st, 2005. Cisplatin-Induced GADD34 Upregulation Potentiates Oncolytic Viral Therapy in the Treatment of Malignant Pleural Mesothelioma
Conclusion: Cisplatin-induced GADD34 expression selectively enhanced the cytotoxicity of the gamma(1)34.5-deficient oncolytic virus, NV1066. This provides a cellular basis for combination therapy with cisplatin and NV1066 to treat MPM and achieve synergistic efficacy, while minimizing dosage and toxicity.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Epithelioid, Full Archive, Gene Therapy, New & Novel, Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
